BioVascular (San Diego, CA) a development stage biotechnology company focused on novel cardiovascular therapeutics closed a $10.8M Series C financing. Participants include BB Biotech Ventures and Domain Associates.

Orqis (Lake Forest, CA) is developing devices to prevent or reverse the underlying disease progression of congestive heart failure has closed a $37.4M Series D financing. New investors include Wasatch Advisors, Cross Creek Capital and the Omega Fund along with Boston Scientific and Lighthouse Capital Partners.

Amira Pharmaceuticals (San Diego, CA) drug company focused on inflammatory respitory and cardiovascular disease solutions via the leukotriene and TNF? pathways closed a $25M Series B financing. The deal was led by Novo AS and joined by Avalon Ventures, Prospect Venture Partners and Versant Ventures.

Microbia (Cambridge, MA) rational drug designer focused on GI and cardiovascular therapeutics raised a $50M series F round. The financing was led by Ridgeback Capital and joined by Morgan Stanley Investment Management.

Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised $5M, bringing the aggregate investment in all rounds into Symphony Medical to $17 million. The only participants in the round were Domain Associates, Johnson & Johnson Development Corp., [...]

Symphony Medical (Laguna Hills, CA) develops proprietary biopolymer and cellular-based biologic therapies to effectively treat chronic and post-operative atrial fibrillation and other cardiac conduction abnormalities, has raised another $11.2M in Series B funding. Participants include Domain Associates, Johnson & Johnson Development Corp., Morgenthaler Ventures, Triathlon Medical Ventures and Guidant Compass Group.